Research Analysts’ Recent Ratings Updates for LB Pharmaceuticals (LBRX)
by Danessa Lincoln · The Markets DailySeveral analysts have recently updated their ratings and price targets for LB Pharmaceuticals (NASDAQ: LBRX):
- 10/9/2026 – LB Pharmaceuticals is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $65.00 price target on the stock.
- 10/6/2026 – LB Pharmaceuticals is now covered by Guggenheim. They set a “buy” rating and a $80.00 price target on the stock.
- 10/5/2026 – LB Pharmaceuticals is now covered by Guggenheim. They set a “buy” rating and a $80.00 price target on the stock.
- 10/5/2026 – LB Pharmaceuticals was downgraded by Roth Capital from “buy” to “neutral”. They now have a $35.00 price target on the stock, down from $37.00.
- 10/3/2026 – LB Pharmaceuticals was downgraded by Wall Street Zen from “sell” to “strong sell”.
- 10/2/2026 – LB Pharmaceuticals is now covered by Needham & Company LLC. They set a “buy” rating and a $68.00 price target on the stock.
- 10/2/2026 – LB Pharmaceuticals is now covered by Needham & Company LLC. They set a “buy” rating and a $68.00 price target on the stock.
- 8/24/2026 – LB Pharmaceuticals had its price target raised by HC Wainwright from $45.00 to $60.00. They now have a “buy” rating on the stock.
- 8/15/2026 – LB Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
- 8/13/2026 – LB Pharmaceuticals was given a new $53.00 price target by Stifel Nicolaus.
- 8/12/2026 – LB Pharmaceuticals had its price target raised by BMO Capital Markets from $46.00 to $54.00. They now have an “outperform” rating on the stock.
- 8/11/2026 – LB Pharmaceuticals was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system and neuropsychiatric disorders. The company’s lead product candidate is LB-102, an oral prodrug of amisulpride, an established antipsychotic medicine that is approved in certain countries outside the United States but is not currently approved in the U.S.
LB-102 is being developed for the treatment of schizophrenia, with the company seeking to evaluate its potential to address the needs of patients and healthcare providers in the U.S.